Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Nephrogenic systemic fibrosis: risk factors and incidence estimation.

Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A.

Radiology. 2007 Apr;243(1):148-57.

PMID:
17267695
2.

Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.

Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.

AJR Am J Roentgenol. 2008 Apr;190(4):1060-8. doi: 10.2214/AJR.07.2822.

PMID:
18356456
3.

Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis?

Saab G, Abu-Alfa A.

Radiology. 2007 Sep;244(3):930-1; author reply 931-2. No abstract available.

PMID:
17709844
4.

Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.

Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC.

Radiology. 2009 Dec;253(3):689-96. doi: 10.1148/radiol.2533090649.

PMID:
19789233
5.

Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?

Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL.

Radiology. 2015 Sep;276(3):741-7. doi: 10.1148/radiol.2015142423.

PMID:
25875973
6.

Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.

Bryant BJ 2nd, Im K, Broome DR.

Clin Radiol. 2009 Jul;64(7):706-13. doi: 10.1016/j.crad.2009.04.004.

PMID:
19520215
7.

Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.

Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J.

Radiology. 2009 Oct;253(1):81-9. doi: 10.1148/radiol.2531082160.

PMID:
19709997
8.

Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.

Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA.

Radiology. 2009 Feb;250(2):371-7. doi: 10.1148/radiol.2502080498.

9.

Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents.

Hoppe H, Spagnuolo S, Froehlich JM, Nievergelt H, Dinkel HP, Gretener S, Thoeny HC.

Eur Radiol. 2010 Mar;20(3):595-603. doi: 10.1007/s00330-009-1586-0.

PMID:
19760239
10.

Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.

Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'Malley RB, Parsons DJ, Fuller ER 3rd, Semelka RC.

Radiology. 2008 Sep;248(3):799-806. doi: 10.1148/radiol.2483072093.

PMID:
18632533
11.

Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.

Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH.

Radiology. 2011 Jul;260(1):105-11. doi: 10.1148/radiol.11102340.

PMID:
21586680
12.

Nephrogenic systemic fibrosis: possible association with a predisposing infection.

Golding LP, Provenzale JM.

AJR Am J Roentgenol. 2008 Apr;190(4):1069-75. doi: 10.2214/AJR.07.2884.

PMID:
18356457
13.

Incidence of nephrogenic systemic fibrosis at two large medical centers.

Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM.

Radiology. 2008 Sep;248(3):807-16. doi: 10.1148/radiol.2483071863.

PMID:
18710976
14.

Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.

Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.

Am J Kidney Dis. 2008 Jun;51(6):966-75. doi: 10.1053/j.ajkd.2007.12.036.

PMID:
18501784
15.

Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.

Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A.

AJR Am J Roentgenol. 2015 Sep;205(3):469-78. doi: 10.2214/AJR.14.14268.

PMID:
26295633
16.

Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH.

Radiology. 2007 Oct;245(1):168-75. Erratum in: Radiology. 2010 Apr;255(1):308.

PMID:
17704357
17.

Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA.

AJR Am J Roentgenol. 2007 Feb;188(2):586-92.

PMID:
17242272
18.

Nephrogenic systemic fibrosis: center case review.

Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-Parker S, Martin DR.

J Magn Reson Imaging. 2007 Nov;26(5):1198-203. Review.

PMID:
17969162
19.

[Nephrogenic systemic fibrosis].

Samtleben W.

Radiologe. 2007 Sep;47(9):778-84. German.

PMID:
17717643
20.

A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.

Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ.

Invest Radiol. 2008 Jan;43(1):65-75.

PMID:
18097279
Items per page

Supplemental Content

Support Center